The relationship of IL-6 and TNF-α levels with glucocorticoid sensitivity in patients with idiopathic Orbital inflammatory pseudotumor
-
摘要:
目的 探讨眼眶炎性假瘤(IOIP)患者血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平与糖皮质激素敏感性的关系。 方法 选取2020年1月—2023年1月徐州市第一人民医院收治的97例IOIP患者,根据糖皮质激素敏感性分为糖皮质激素敏感组(62例)及抵抗组(35例),比较2组IL-6、TNF-α水平及疾病活动性,分析相关性,采用ROC曲线评估各指标对糖皮质激素敏感性的预测价值。 结果 抵抗组血清IL-6、TNF-α水平及活动期患者占比[(2.24±0.28)pg/mL、(1.95±0.22)pg/mL、65.71%(23/35)]均高于敏感组[(1.89±0.33)pg/mL、(1.45±0.31)pg/mL、43.55%(27/62),P<0.05]。敏感组活动期患者血清IL-6、TNF-α水平均高于非活动期患者(P<0.05);抵抗组活动期患者血清IL-6、TNF-α水平均高于非活动期患者(P<0.05)。Spearman相关分析显示,IL-6、TNF-α水平与IOIP患者疾病活动性均呈正相关关系(r=0.433、0.396,P<0.05)。ROC曲线显示,IL-6、TNF-α水平预测糖皮质激素敏感性的曲线下面积分别为0.689、0.698(P<0.05)。 结论 血清IL-6、TNF-α在糖皮质激素抵抗IOIP患者中表达较高,可预测糖皮质激素敏感性。 Abstract:Objective To investigate the relationship between serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) levels, and glucocorticoid sensitivity in patients with idiopathic orbital inflammatory pseudotumor (IOIP). Methods A total of 97 IOIP patients admitted to Xuzhou First People ' s Hospital from January 2020 to January 2023 were selected and divided into the glucocorticoid-sensitive group (n=62) and the resistance group (n=35) according to glucocorticoid sensitivity. The levels of IL-6 and TNF-α and disease activity were observed, the correlation was analyzed. The ROC curve was used to evaluate the predictive value of each index for the sensitivity of glucocorticoids. Results The serum levels of IL-6 and TNF-α in the resistance group and the proportion of patients in the active stage [(2.24±0.28) pg/mL, (1.95±0.22) pg/mL, 65.71% (23/35)] were higher than those in the sensitive group [(1.89±0.33) pg/mL, (1.45±0.31)pg/mL, 43.55%(27/62), P < 0.05]. The serum levels of IL-6 and TNF-α in the active patients in the sensitive group were higher than those in the inactive patients (P < 0.05); the serum levels of IL-6 and TNF-α in the active patients in the resistance group were higher than those in the inactive patients (P < 0.05). Spearman correlation analysis showed that the levels of IL-6 and TNF-α were positively correlated with the disease activity in the IOIP patients (r=0.433, 0.396, P < 0.05). ROC curve showed that IL-6 and TNF-α levels predicted glucocorticoid sensitivity with a score below the curve of 0.689 and 0.698 (P < 0.05). Conclusion Serum IL-6 and TNF-α expression is higher in patients with glucocorticoid resistance to IOIP, which can predict glucocorticoid sensitivity. -
表 1 不同糖皮质激素敏感性IOIP患者临床资料比较
Table 1. Comparison of clinical data of IOIP patients with different glucocorticoid sensitivities
组别 例数 性别(例) 年龄(x ±s,岁) 病程(x ±s,月) 疾病部位(例) 男性 女性 单眼 双眼 敏感组 62 29 33 41.22±3.08 3.56±0.45 48 14 抵抗组 35 14 21 40.98±3.11 3.39±0.67 29 6 统计量 0.416a 0.367b 1.491b 0.404a P值 0.519 0.714 0.139 0.525 注:a为χ2值,b为t值。 表 2 不同糖皮质激素敏感性IOIP患者血清IL-6、TNF-α水平及疾病活动性比较
Table 2. Comparison of serum IL-6 and TNF-α levels and disease activity in IOIP patients with different glucocorticoid sensitivities
组别 例数 IL-6 (x ±s,pg/mL) TNF-α (x ±s,pg/mL) 疾病活动期[例(%)] 敏感组 62 1.89±0.33 1.45±0.31 27(43.55) 抵抗组 35 2.24±0.28 1.95±0.22 23(65.71) 统计量 5.289a 8.412a 4.401b P值 <0.001 <0.001 0.036 注:a为t值,b为χ2值。 表 3 不同疾病时期IOIP患者血清IL-6、TNF-α水平比较(x ±s,pg/mL)
Table 3. Comparison of serum IL-6 and TNF-α levels in IOIP patients at different disease stages(x ±s, pg/mL)
组别 例数 IL-6 TNF-α 活动期 50 2.33±0.37 2.04±0.26 非活动期 47 1.78±0.27 1.11±0.29 t值 8.318 16.649 P值 <0.001 <0.001 表 4 敏感组疾病不同疾病时期IOIP患者治疗前后血清IL-6、TNF-α水平比较(x ±s,pg/mL)
Table 4. Comparison of serum IL-6 and TNF-α levels across different disease stages in sensitive-group IOIP patients, before and after treatment(x ±s, pg/mL)
组别 例数 IL-6 t值 P值 TNF-α t值 P值 治疗前 治疗后 治疗前 治疗后 活动期 27 2.11±0.29 1.21±0.21 18.706 <0.001 1.88±0.24 0.83±0.16 27.280 <0.001 非活动期 35 1.72±0.36 1.13±0.34 10.947 <0.001 1.07±0.36 0.77±0.12 7.395 <0.001 统计量 4.593a 0.410b 10.081a 0.410b P值 <0.001 0.525 <0.001 0.128 注:a为t值,b为F值。 表 5 抵抗组疾病不同疾病时期IOIP患者治疗前后血清IL-6、TNF-α水平比较(x ±s,pg/mL)
Table 5. Comparison of serum IL-6 and TNF-α levels across different disease stages in resistant-group IOIP patients, before and after treatment(x ±s, pg/mL)
组别 例数 IL-6 t值 P值 TNF-α t值 P值 治疗前 治疗后 治疗前 治疗后 活动期 23 2.59±0.44 1.09±0.23a 21.474 <0.001 2.23±0.28 0.73±0.11 36.891 <0.001 非活动期 12 1.57±0.03 0.96±0.17a 36.088 <0.001 1.21±0.11 0.69±0.12 26.751 <0.001 统计量 7.964a 1.123b 12.072a 0.286b P值 <0.001 0.297 <0.001 0.595 注:a为t值,b为F值。 表 6 不同糖皮质激素敏感性患者不同疾病活动期血清IL-6、TNF-α水平比较(x ±s,pg/mL)
Table 6. Comparison of serum IL-6 and TNF-α levels across different disease stages in sensitive-group IOIP patients(x ±s, pg/mL)
组别 例数 活动期 例数 非活动期 IL-6 TNF-α IL-6 TNF-α 敏感组 27 2.11±0.29 1.88±0.24 35 1.72±0.36 1.07±0.36 抵抗组 23 2.59±0.44 2.23±0.28 12 1.57±0.03 1.21±0.11 t值 4.616 4.761 1.431 1.318 P值 <0.001 <0.001 0.159 0.194 表 7 IL-6、TNF-α水平预测糖皮质激素敏感性的效能
Table 7. The efficacy of IL-6 and TNF-α levels in predicting the sensitivity of glucocorticoids
项目 cut-off值 AUC 95% CI 约登指数 灵敏度(%) 特异度(%) P值 IL-6 ≤2.21 pg/mL 0.689 0.587~0.779 0.382 83.87 54.29 0.001 TNF-α ≤1.67 pg/mL 0.698 0.597~0.787 0.420 67.74 74.29 < 0.001 -
[1] 孟海燕, 杨维佳, 黄慧莲, 等. 彩色多普勒超声、MRI动态增强对眼内或眶内占位病变诊断及监测价值[J]. 中国CT和MRI杂志, 2022, 20(9): 28-29.HUANG Y Y, BI J, CHEN X, et al. Clinical value of Logistic regression model based on clinical and ultrasonographic features for the differential diagnosis of orbital and ocular adnexal lymphoma and inflammatory pseudotumour[J]. Chinese Journal of CT and MRI, 2022, 20(9): 28-29. [2] 杨华胜, 张特, 叶慧菁. 基于影像学分类的眼眶炎性假瘤诊疗方法选择[J]. 中华眼科杂志, 2023, 59(1): 8-12.YANG H S, ZHANG T, YE H J. Role of imaging classification in the diagnosis and management of orbital inflammatory pseudotumor[J]. Chin J Ophthalmol, 2023, 59(1): 8-12. [3] 王丽, 韩宜男, 王胜资. 难治性眼眶炎性假瘤放射治疗后的疗效评估[J]. 中国眼耳鼻喉科杂志, 2021, 21(4): 255-259, 263.WANG L, HAN Y N, WANG S Z. Evaluation of the clinical response after radiotherapy in patients with refractory orbital pseudotumor[J]. Chin J Ophthalmol otorhinolaryngol, 2021, 21(4): 255-259, 263. [4] 赵唯, 陶定波, 郑红亮, 等. 以眼部肌肉肿胀、视力下降为主要表现的IgG4相关性眼病1例[J]. 大连医科大学学报, 2023, 45(2): 174-177.ZHAO W, TAO D B, ZHENG H L, et al. A case of IgG4-related ophthalmic disease with ocular muscle swelling and visual acuity loss as the main symptoms[J]. J Dalian Med Univ, 2023, 45(2): 174-177. [5] 张超, 魏兵, 付金月, 等. 哮喘儿童对吸入性糖皮质激素用药依从性及影响因素[J]. 西部医学, 2022, 34(9): 1366-1370.ZHANG C, WEI B, FU J Y, et al. Compliance and influencing factors of inhaled corticosteroids in children with asthma[J]. Med J West Chin, 2022, 34(9): 1366-1370. [6] 钟烁, 苗伟. 慢性鼻-鼻窦炎伴鼻息肉患者鼻黏膜组织HIF-1α、MUC5AC表达与糖皮质激素抵抗的关系[J]. 新疆医科大学学报, 2023, 46(4): 441-446.ZHONG S, MIAO W. Relationship between expression of HIF-1α and MUC5AC in nasal mucosa and glucocorticoid resistance in patients with chronic rhinosinusitis and nasal polyps[J]. J Xinjiang Med Univ, 2023, 46(4): 441-446. [7] 金蕊, 马建民, 马雪梅, 等. 眼眶炎性假瘤中IL-1β和IL-6表达的研究[J]. 山东医药, 2010, 50(20): 31-33.JIN R, MA J M, MA X M, et al. Expression of IL-1β and IL- 6 in patients with idiopathic orbital inflammatory pseudotumors[J]. Shandong Med J, 2010, 50(20): 31-33. [8] 李海燕, 王道芸, 黄莉. 眼眶炎性假瘤多层螺旋CT、磁共振影像学表现及诊断价值研究[J]. 中国CT和MRI杂志, 2021, 19(10): 22-24.LI H Y, WANG D Y, HUANG L. Imaging features of the orbital inflammatory pseudotumor in the multi-slice spiral CT and magnetic resonance imaging and its diagnostic value[J]. Chin J CT MRI, 2021, 19(10): 22-24. [9] 赵军阳, 朱建波. 局部注射长效激素在不同类型眼眶炎性假瘤治疗中的应用[J]. 中国斜视与小儿眼科杂志, 2016, 24(2): 27-30, 中插3.ZHAO J Y, ZHU J B. Focal therapy for the different types of orbital inflammatory pseudo-tumor[J]. Chin J Strabis Pediat Ophthalmol, 2016, 24(2): 27-30, 中插3. [10] SHIELDS J A, SHIELDS C L. Orbital pseudotumor versus idiopathic nongranulomatous orbital inflammation[J]. Ophthalmic Plast Reconstr Surg, 2013, 29(5): 349. DOI: 10.1097/IOP.0b013e3182a65109. [11] 翟孟凡, 谢立科, 郝晓凤, 等. 基于CiteSpace的眼眶炎性假瘤的可视化分析[J]. 中国医药导报, 2024, 21(6): 8-14.ZHAI M F, XIE L K, HAO X F, et al. Visualization analysis of orbital inflammatory pseudotumor based on Cite-Space[J]. Chin Med Herald, 2024, 21(6): 8-14. [12] 俞国松, 阮善平, 赵志新, 等. Lvis和Solitaire支架辅助弹簧圈治疗未破裂宽颈眼动脉段动脉瘤的效果比较[J]. 中华全科医学, 2022, 20(9): 1502-1505, 1516. doi: 10.16766/j.cnki.issn.1674-4152.002634YU G S, RUAN S P, ZHAO Z X, et al. A comparative study of clinical efficacy and safety between Lvis and Solitaire stent-assisted embolization for unruptured wide-necked ophthalmic segment aneurysms of internal carotid artery[J]. Chinese Journal of General Practice, 2022, 20(9): 1502-1505, 1516. doi: 10.16766/j.cnki.issn.1674-4152.002634 [13] 陈子扬, 谢立科, 郝晓凤, 等. 谢立科治疗糖皮质激素依赖性眼眶炎性假瘤经验撷菁[J]. 中国中医眼科杂志, 2024, 34(9): 846-848, 853.CHEN Z Y, XIE L K, HAO X F, et al. Professor XIE Like's treatment experience of Hormone-dependent orbital pseudotu-mor[J]. Chin J Chin Ophthalmol, 2024, 34(9): 846-848, 853. [14] 仲颖, 陈静巧, 徐龙江, 等. 以眼眶炎性假瘤和双肺多发结节为主要表现的未成年IgG4相关性疾病1例[J]. 中华风湿病学杂志, 2022, 26(9): 628-631, F3.ZHONG Y, CHEN J Q, XU L J, et al. A case of IGG4-related disease in a juvenile with orbital inflammatory pseudotumor and multiple pulmonary nodule[J]. Chinese Journal of Rheumatol, 2022, 26(9): 628-631, F3. [15] 黄游义, 毕洁, 陈晓, 等. 基于临床和超声图像特征的Logistic回归模型鉴别诊断眼眶及眼附件淋巴瘤与炎性假瘤的临床价值[J]. 临床超声医学杂志, 2023, 25(2): 105-109.HUANG Y Y, BI J, CHEN X, et al. Clinical value of Logistic regression model based on clinical and ultrasonographic features for the differential diagnosis of orbital and ocular adnexal lymphoma and inflammatory pseudotumour[J]. J Clin Ultras Med, 2023, 25(2): 105-109. [16] 靳玮, 张黎, 李谦, 等. 根皮素对白细胞介素-1β诱导Graves眼病眼眶成纤维细胞中炎症反应和氧化应激的抑制作用及其机制[J]. 中华实验眼科杂志, 2023, 41(3): 233-240.JIN W, ZHANG L, LI Q, et al. Inhibitory effect of phloretin on inflammation and oxidative stress in IL-1β induced orbital fibroblasts in Graves orbitopathy and its mechanism[J]. Chin J Exp Ophthalmol, 2023, 41(3): 233-240. [17] 赵珂, 马建民, 肖飞, 等. IL-6、TNF-α、GR-α、GR-βmRNA与常见眼眶疾病患者对糖皮质激素敏感性的关系[J]. 首都医科大学学报, 2021, 42(5): 747-753.ZHAO K, MA J M, XIAO F, et al. Application of the mRNA of IL-6, TNF-α, GR-α and GR-β in evaluating the glucocorticoids sensitivity of patients with common orbital diseases[J]. J Capital Med Univ, 2021, 42(5): 747-753. [18] 谢荣荣, 史婷婷, 信中, 等. Graves眼病患者血浆细胞因子浓度与临床活动度的相关性分析[J]. 首都医科大学学报, 2023, 44(3): 407-412.XIE R R, SHI T T, XIN Z, et al. Analysis of the correlation between levels of cytokines and the clinical active severity in patients with Graves ' ophthalmopathy[J]. J Capital Med Univ, 2023, 44(3): 407-412. -
下载: